PreveCeutical Medical Inc (CSE:PREC) (OTCQB:PRVCF) announced Wednesday that it has successfully demonstrated that the delivery efficiency of its diabetes-targeting Dual Gene Therapy Research Program could be tailored based on vector composition.
The company has identified a promising modified delivery vector based on stable small interfering RNA (siRNA) for possible preclinical experiments. The iRNA gets incorporated within the delivery vehicle, with strong cell entry and cargo release, and minimal toxicity.
These delivery systems have the potential to combine the benefits of silencing RNAi (ribonucleic acid interference) and modified delivery vectors, the company said.
“The current results PreveCeutical has received is very exciting to us and shows a very high probability of success that will now allow us to move to the completion stage of the program,” CEO Stephen Van Deventer said in a statement.
From here, PreveCeutical plans to proceed with the optimization of the delivery system that will be tested in animal models.
Ultimately, the idea is to down-regulate a particular gene of interest, which impacts Type 2 diabetes and obesity.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
The company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the cannabidiols sol-gel program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
Contact Andrew Kessel at firstname.lastname@example.org
Follow him on Twitter @andrew_kessel